## Edgar Filing: ARRAY BIOPHARMA INC - Form 4/A

ARRAY BIC Form 4/A April 06, 201	PHARMA INC	C									
										PPROVAL	
Washington					IES AND EXCHANGE COMMISSION agton, D.C. 20549			OMB Number:	3235-0287		
Check this if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er <b>STATE</b> 5. Filed pu <sup>18</sup> Section 17	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						burden hou response	Estimated average burden hours per response 0.5		
(Print or Type R	esponses)										
MOORE JOHN R Symbo ARRA			Symbol	AY BIOPHARMA INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				of Earliest Transaction /Day/Year) /2017				Director       10% Owner         Officer (give title       Other (specify below)         VP, General Counsel			
			endment, Date Original nth/Day/Year) 017				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table	e I - Non-D	erivative <b>S</b>	Securi	ities Aco	quired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Yea	r) Execution any	emed	3. Transactic Code (Instr. 8)	4. Securi on(A) or Di (D)	ties Adispose 4 and (A) or	cquired d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	04/01/2017			F	6,370 (1)	D	\$ 8.94	40,102	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. iorNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Under Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: ARRAY BIOPHARMA INC - Form 4/A

## **Reporting Owners**

Reporting Owner Name / Ad	dress	Relationships						
http://mg o where i where i i w	Director	10% Owner	Officer	Other				
MOORE JOHN R C/O ARRAY BIOPHARMA 3200 WALNUT STREET BOULDER, CO 80301	A INC.		VP, General Counsel					
Signatures								
John R. Moore	04/06/2017							
<u>**</u> Signature of	Date							

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations (1) in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person